article thumbnail

The rise of prescription drug abuse and drug diversion

pharmaphorum

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market.

article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Voice is Becoming the Loudest Tool in the Exam Room

PM360

The line from the 2011 Pixar “Cars” sequel (trust me, as a parent of two, I have seen it countless times) points to the practical implication for voice technology. While this sort of innovation might not be a surprise in the automotive category, its breadth of functional benefits for patients and healthcare providers (HCPs) might be.

article thumbnail

PM360 2022 Trailblazer Awards Supplier/Vendor of the Year GoodRx

PM360

Through the GoodRx App, savings cards, and their website, GoodRx has saved Americans over $35 billion on prescriptions and avoid $60 million in hospitalization costs since 2011. GoodRx has recently created unique tools for healthcare providers to better care for their patients.

article thumbnail

Specialty Treatments Require a New Approach to Affordability

PM360

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

This class-action litigation specifically focused on a 2011 licensing agreement between the two companies. Ex-Novartis sales representative Steven Camburn filed a whistleblower case that claimed Novartis had paid doctors up to $3,500 to participate in educational speaker programs to increase the promotion and prescription of Gilenya.